Effect of Genetic Variation in CYP450 on Gonadal Impairment in a European Cohort of Female Childhood Cancer Survivors, Based on a Candidate Gene Approach: Results from the PanCareLIFE Study.
M E Madeleine van der PerkLinda BroerYutaka YasuiLeslie L RobisonMelissa M HudsonJoop S E LavenHelena J van der PalWim J E TissingBirgitta VersluysDorine BrestersGertjan J L KaspersAndrica C H de VriesCornelis B LambalkAnnelies OverbeekJacqueline J LoonenCatharina C M BeerendonkJulianne ByrneClaire BergerEva ClemensUta DirksenJeanette Falck WintherSophie D FossåDesiree GrabowMonica MuracaMelanie KaiserTomáš KepákJarmila KruseováDalit Modan-MosesClaudia SpixOliver ZolkPeter KaatschJesse H KrijtheLeontien C M KremerRussell John BrookeJessica L BaedkeRon H N van SchaikJohn N van den AnkerAndré G UitterlindenAnnelies M E BosFlora E van LeeuwenEline van Dulmen-den BroederAnne-Lotte L F van der KooiMarry M van den Heuvel-Eibrinknull On Behalf Of The PanCareLIFE ConsortiumPublished in: Cancers (2021)
Female CCSs CYP3A4*3 carriers had significantly lower AMH levels, and CYP2B6*2 may have a protective effect on AMH levels. Identification of risk-contributing variants may improve individualized counselling regarding the treatment-related risk of infertility and fertility preservation options.